Portfolio Details

GreenLight Biosciences, Inc.

Greenlight Biosciences company logo
Exited

GreenLight is a bio-performance company with a unique, cell-free production platform that delivers high-performing RNA solutions to human, plant and animal challenges.

Baird Capital invests in the Technology & Services sector, including tech business services, as well as businesses that provide services directly or indirectly to the healthcare industry. Baird Capital and predecessor entities previously made investments in MedTech including investments in medical tools (e.g., DNA analysis), Medical devices (e.g., bladder control, heart valves, surgical robotics, etc.) and certain areas of Industrials and Consumer Products. 

Learn more about the company
Greenlight Biosciences company logo
Exited
Team
Venture Capital
Invested Date
January 2019
Status
Exited
Location
U.S.

Share

See All Transactions

Related Content

Dropper adding sample to a test tube
GreenLight Biosciences Goes Public

Baird Capital portfolio company GreenLight Biosciences (GreenLight) officially started trading on Nasdaq as a public company.

Abstract blue shapes
GreenLight to Become Publicly Traded Company

The transaction hopes to advance GreenLight’s breakthrough biomanufacturing platform.

GreenLight Raises $102M Series D Round

Baird Capital portfolio company GreenLight Biosciences (GreenLight) announced it raised an oversubscribed $102 million Series D round of funding from new and existing investors.

Medical professional holding iPad while wearing lab coat
GreenLight Raises $17M for COVID-19 Vaccine Production

GreenLight Biosciences announced it had closed an oversubscribed $17M special purpose funding round to build out its scalable mRNA production capability targeting the production of billions of doses of COVID-19 vaccine.